Chantal Quinten of the EORTC Quality of Life Department receives the 2010 ISOQOL Young Investigator Award
15 Dec 2010
Each year the International Society for Quality of Life (ISOQOL) recognizes the best presentations made by investigators in the early stages of their career in QOL research. This year, during its annual conference held on 30 October 2010 in London, Chantal Quinten of the EORTC Quality of Life Department received the Young Investigator Award for her research entitled: “Investigating heterogeneity for survival in a pooled cancer cohort of closed EORTC Randomized Controlled Trials”.[1]
Chantal, together with her colleagues from the EORTC Quality of Life PROBE (Patient Reported Outcomes and Behavioral Evidence) team (www.eortc.be/probe), investigated in a pooled dataset of closed EORTC clinical studies, the prognostic value of clinical and health related quality of life (HRQOL) variables for survival taking into account heterogeneity in survival across the different cancer sites included in that dataset. Their analysis compared a stratified Cox model with a Cox model which included cancer site as a random effect (frailty).
Both Cox models retained the same clinical (age, gender, WHO performance status and metastasis) and HRQOL (physical functioning, pain, appetite loss) parameters as being significant, yet the frailty model provides smaller confidence intervals. Further analyses are currently being performed to investigate trial and treatment as frailties in addition to cancer site as a frailty term. The application of these models to the analysis of survival data may open up new opportunities for the analysis of survival studies using QOL data.
John Bean
[1] C. Quinten, F. Martinelli, C. Coens, J. Maringwa, C. Cleeland, H. Flecthner, C. Gotay, E. Greimel, M. King, D. Osoba, M.J.H. Taphoorn, B. Reeve, J. Ringash, J. Shmucker-Von Koch, J. Weis, A. Bottomley. Prognostic significance of patient heterogeneity in a dataset of 10,108 cancer patients. Quality of Life Research 19(1): 144, 2010.
Related News
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer
17 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
Interview of ROSC Chair, Joost Vaerhoeff
28 Apr 2026